Expand SXTPW Menu
SXTPW MENU

SXTPW Latest Press Releases

-- July 30, 2026 --

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules Globe Newswire 2:23 PM

-- July 29, 2026 --

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 Globe Newswire 4:03 PM

-- July 8, 2026 --

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases Globe Newswire 8:01 AM

-- July 1, 2026 --

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue Globe Newswire 8:02 AM

-- June 11, 2026 --

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement Globe Newswire 8:03 AM

-- May 26, 2026 --

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis Globe Newswire 8:02 AM

-- May 15, 2026 --

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results Globe Newswire 8:42 AM

-- April 15, 2026 --

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website Globe Newswire 8:02 AM

-- March 31, 2026 --

60 Degrees Pharmaceuticals Announces 2025 Annual Results Globe Newswire 7:01 AM

-- March 18, 2026 --

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract Globe Newswire 8:01 AM

-- March 11, 2026 --

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial Globe Newswire 7:24 AM
Market Data Delayed 15 Minutes